Deubiquitinase OTUD7B is a Potential Prognostic Biomarker in Diffuse Large B-cell Lymphoma

Overview

Journal J Cancer

Specialty Oncology

Date 2022 Feb 14

PMID 35154465

Authors

Shi Qiu

Yizhen Liu

Ailing Gui

Zuguang Xia

Wen Liu

Juan J Gu

Ji Zuo

Ling Yang

Qunling Zhang

Affiliations

Soon will be listed here.

Abstract

OTUD7B is a deubiquitinase and has been reported as a prognostic factor in various solid tumors. However, its prognostic value in lymphoma patients remains unclear. We detected OTUD7B expression levels in 160 diffuse large B-cell lymphoma (DLBCL) tissue samples by immunohistochemistry, and analyzed correlations between its expression and clinic-pathologic parameters as well as clinical outcomes. We also investigated association between OTUD7B expression and chemotherapeutic drugs anti-tumor activity in vitro. We found that OTUD7B overexpressed in 129 (80.6%) cases, and patients with overexpression of OTUD7B experienced better overall survival comparing to those with OTUD7B low expression (=0.021). Multivariate Cox regression analysis illustrated that OTUD7B was an independent prognostic indicator. In DLBCL cell lines, we found that Chidamide could up-regulate OTUD7B in several DLBCL cell lines, and also had synergistic effect with doxorubicin at low concentration. Our data illustrated that OTUD7B deficiency is a negative predictor of clinical outcome, and might be a potential therapeutic target in the treatment of diffuse large B-cell lymphoma.

Citing Articles

Reduced OTUD7B expression correlates with poor prognosis in PTCL via non-canonical NF-κB.

Chen F, Qiu S, Gui A, Jiang S, Yan Y, Wu J Int J Hematol. 2024; 121(2):194-205.

PMID: 39636331 DOI: 10.1007/s12185-024-03877-y.

OTUD7B knockdown inhibits the proliferation and stemness of breast cancer cells by destabilizing FOXM1.

Wang H, Han S, Xiao J, Fu X, Chen W, Zhuo D Oncol Lett. 2024; 27(3):102.

PMID: 38298430 PMC: 10829069. DOI: 10.3892/ol.2024.14235.

Epigenetic alterations and advancement of lymphoma treatment.

Zhuang S, Yang Z, Cui Z, Zhang Y, Che F Ann Hematol. 2023; 103(5):1435-1454.

PMID: 37581713 DOI: 10.1007/s00277-023-05395-z.

AtomNet-Aided OTUD7B Inhibitor Discovery and Validation.

Chen J, Bolhuis D, Laggner C, Kong D, Yu L, Wang X Cancers (Basel). 2023; 15(2).

PMID: 36672466 PMC: 9856706. DOI: 10.3390/cancers15020517.

References

Hu H, Wang H, Xiao Y, Jin J, Chang J, Zou Q . Otud7b facilitates T cell activation and inflammatory responses by regulating Zap70 ubiquitination. J Exp Med. 2016; 213(3):399-414. PMC: 4813674. DOI: 10.1084/jem.20151426. View

Yao S, Li J, Yao Z, Xu Y, Chu J, Zhang J . Extranodal involvement in young patients with diffuse large B-cell lymphoma: distribution, prognostic value and treatment options. Chin J Cancer Res. 2017; 29(1):57-65. PMC: 5348476. DOI: 10.21147/j.issn.1000-9604.2017.01.07. View

LEsperance S, Popa I, Bachvarova M, Plante M, Patten N, Wu L . Gene expression profiling of paired ovarian tumors obtained prior to and following adjuvant chemotherapy: molecular signatures of chemoresistant tumors. Int J Oncol. 2006; 29(1):5-24. View

Guan X, Wang H, Ban W, Chang Z, Chen H, Jia L . Novel HDAC inhibitor Chidamide synergizes with Rituximab to inhibit diffuse large B-cell lymphoma tumour growth by upregulating CD20. Cell Death Dis. 2020; 11(1):20. PMC: 6944697. DOI: 10.1038/s41419-019-2210-0. View

Wang B, Jie Z, Joo D, Ordureau A, Liu P, Gan W . TRAF2 and OTUD7B govern a ubiquitin-dependent switch that regulates mTORC2 signalling. Nature. 2017; 545(7654):365-369. PMC: 5695540. DOI: 10.1038/nature22344. View

Nikolaou K, Tsagaratou A, Eftychi C, Kollias G, Mosialos G, Talianidis I . Inactivation of the deubiquitinase CYLD in hepatocytes causes apoptosis, inflammation, fibrosis, and cancer. Cancer Cell. 2012; 21(6):738-50. DOI: 10.1016/j.ccr.2012.04.026. View

Chiu H, Lin H, Tseng I, Lin Y . upregulation predicts a poor response to paclitaxel in patients with triple-negative breast cancer. Oncotarget. 2018; 9(1):553-565. PMC: 5787489. DOI: 10.18632/oncotarget.23074. View

Kubuschok B, Held G, Pfreundschuh M . Management of diffuse large B-cell lymphoma (DLBCL). Cancer Treat Res. 2015; 165:271-88. DOI: 10.1007/978-3-319-13150-4_11. View

Bonacci T, Suzuki A, Grant G, Stanley N, Cook J, Brown N . Cezanne/OTUD7B is a cell cycle-regulated deubiquitinase that antagonizes the degradation of APC/C substrates. EMBO J. 2018; 37(16). PMC: 6092620. DOI: 10.15252/embj.201798701. View

10.

Li Q, Huang J, Ou Y, Li Y, Wu Y . Progressive diffuse large B-cell lymphoma with TP53 gene mutation treated with chidamide-based chemotherapy. Immunotherapy. 2019; 11(4):265-272. DOI: 10.2217/imt-2018-0083. View

11.

Wang J, Zhong X, Zhang Y, Wu X, Li S, Jian P . Cezanne predicts progression and adjuvant TACE response in hepatocellular carcinoma. Cell Death Dis. 2017; 8(9):e3043. PMC: 5636974. DOI: 10.1038/cddis.2017.428. View

12.

Hu H, Brittain G, Chang J, Puebla-Osorio N, Jin J, Zal A . OTUD7B controls non-canonical NF-κB activation through deubiquitination of TRAF3. Nature. 2013; 494(7437):371-4. PMC: 3578967. DOI: 10.1038/nature11831. View

13.

Enesa K, Zakkar M, Chaudhury H, Luong L, Rawlinson L, Mason J . NF-kappaB suppression by the deubiquitinating enzyme Cezanne: a novel negative feedback loop in pro-inflammatory signaling. J Biol Chem. 2008; 283(11):7036-45. DOI: 10.1074/jbc.M708690200. View

14.

Wang J, Wei W, Guo Z, Shi M, Guo R . Decreased Cezanne expression is associated with the progression and poor prognosis in hepatocellular carcinoma. J Transl Med. 2015; 13:41. PMC: 4329219. DOI: 10.1186/s12967-015-0396-1. View

15.

Pang Z, Cui L, Ding N, Zhu L, Qu X, Dong W . Expressions of insulin-like growth factor receptor-1 and cezanne-1 in lung adenocarcinoma. Med Oncol. 2017; 34(5):78. DOI: 10.1007/s12032-017-0934-1. View

16.

Zhang M, Fang Y, Wang L, Cheng S, Fu D, He Y . Clinical efficacy and molecular biomarkers in a phase II study of tucidinostat plus R-CHOP in elderly patients with newly diagnosed diffuse large B-cell lymphoma. Clin Epigenetics. 2020; 12(1):160. PMC: 7585299. DOI: 10.1186/s13148-020-00948-9. View

17.

Lin D, Shen Y, Qiao S, Liu W, Zheng L, Wang Y . Upregulation of OTUD7B (Cezanne) Promotes Tumor Progression via AKT/VEGF Pathway in Lung Squamous Carcinoma and Adenocarcinoma. Front Oncol. 2019; 9:862. PMC: 6749047. DOI: 10.3389/fonc.2019.00862. View

18.

McNally R, Davis B, Clements C, Accavitti-Loper M, Mak T, Ting J . DJ-1 enhances cell survival through the binding of Cezanne, a negative regulator of NF-kappaB. J Biol Chem. 2010; 286(6):4098-106. PMC: 3039338. DOI: 10.1074/jbc.M110.147371. View

19.

Ruppert A, Dixon J, Salles G, Wall A, Cunningham D, Poeschel V . International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI. Blood. 2020; 135(23):2041-2048. DOI: 10.1182/blood.2019002729. View

20.

Jost P, Ruland J . Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood. 2006; 109(7):2700-7. DOI: 10.1182/blood-2006-07-025809. View